Charles Cherington 13D and 13G filings for Eterna Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-04 10:55 am Purchase |
2025-04-02 | 13D | Eterna Therapeutics Inc. ERNA |
Charles Cherington | 20,432,634 32.800% |
3,790,451 (+22.78%) |
Filing |
| 2025-03-05 5:55 pm Purchase |
2024-10-29 | 13D | Eterna Therapeutics Inc. ERNA |
Charles Cherington | 16,642,183 32.380% |
15,429,657 (+1272.52%) |
Filing |
| 2023-12-22 12:05 pm Unchanged |
2023-12-14 | 13D | Eterna Therapeutics Inc. ERNA |
Charles Cherington | 1,212,526 19.990% |
0 (Unchanged) |
Filing |
| 2023-09-07 5:26 pm Purchase |
2023-07-13 | 13D | Eterna Therapeutics Inc. ERNA |
Charles Cherington | 1,212,526 19.990% |
645,000 (+113.65%) |
Filing |
| 2022-12-14 4:30 pm Purchase |
2022-12-02 | 13D | Eterna Therapeutics Inc. ERNA |
Charles Cherington | 567,526 11.050% |
567,526 (New Position) |
Filing |